Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9 (1), 187

Exosomes Derived From Human Adipose Tissue-Derived Mesenchymal Stem Cells Alleviate Atopic Dermatitis


Exosomes Derived From Human Adipose Tissue-Derived Mesenchymal Stem Cells Alleviate Atopic Dermatitis

Byong Seung Cho et al. Stem Cell Res Ther.


Exosomes are nano-sized vesicles (30-200 nm) constantly released by almost all cells. The ability of exosomes to travel between cells and deliver their cargo, which includes lipids, proteins, and nucleic acids, makes them an appealing cell-free therapy option to treat multiple diseases. Here, we investigated for the first time whether human adipose tissue-derived mesenchymal stem cell-derived exosomes (ASC-exosomes) can ameliorate atopic dermatitis (AD) in an in vivo mouse model. When injected either intravenously (IV) or subcutaneously (SC) into NC/Nga mice treated with house dust mite antigens, ASC-exosomes were found to reduce pathological symptoms such as clinical score, the levels of serum IgE, the number of eosinophils in blood, and the infiltration of mast cells, CD86+, and CD206+ cells in skin lesions. ASC-exosomes also significantly reduced mRNA expression of various inflammatory cytokines such as interleukin (IL)-4, IL-23, IL-31, and tumor necrosis factor-α (TNF-α) in AD skin lesions of Nc/Nga mice. Taken together, these results suggest that ASC-exosomes can be a novel promising cell-free therapeutic modality for AD treatment.

Keywords: Adipose tissue-derived mesenchymal stem cells; Atopic dermatitis; Exosome; Inflammation.

Conflict of interest statement

Ethics approval

The animal study was approved by the Institutional Animal Care and Use Committee and performed in accordance with the Animal Experimentation Policy.

Consent for publication

Not applicable.

Competing interests

BSC and YWY are founders and stockholders of ExoCoBio Inc. All authors are employees of ExoCoBio Inc.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Fig. 1
Fig. 1
Therapeutic effects of ASC-exosomes on AD-like lesions in NC/Nga mice. a The study protocol. b Representative skin manifestations in NC/Nga mice at days 0 and 28, H&E staining results, toluidine blue staining results, and immunohistochemical staining of CD86+ or CD206+ cells of ear skin samples from AD mice. Enlarged images of toluidine blue staining for mast cells and immunostaining for CD86 and CD206 are shown in Additional file 1: Figures S4–S6, respectively. Indicated amounts of ASC-exosomes (micrograms/head) were administered either by IV or SC thrice a week for 4 weeks. c Relative percentage improvement of clinical skin severity scores compared to vehicle group. Percentage improvement was calculated as described in Additional file 1: Materials and methods. d Improvement of ear thickness as measured in H&E-stained tissue sections in b. e The number of mast cells in the skin lesions determined in toluidine blue-stained tissue sections in b. Quantitative analysis of CD86+ (f) and CD206+ (g) cells as determined in tissue sections in b. Results are presented as mean ± standard error of the mean; n = 10 for each group. *P < 0.05, **P < 0.01, and ***P < 0.001 vs vehicle control group. IV intravenous administration, SC subcutaneous administration, Pred prednisolone
Fig. 2
Fig. 2
The effect of ASC-exosomes on the level of serum IgE, the number of eosinophils, and the expression of pro-inflammatory cytokines in NC/Nga mice. a The level of serum IgE was detected by ELISA. b The number of eosinophils in blood was determined by differential cell counting. cf Total RNA was isolated and the mRNA levels of IL-4 (c), IL-31 (d), TNF-α (e), and IL-23 (f) were detected by quantitative real-time PCR and normalized by GAPDH mRNA expression. Results are presented as mean ± standard error of the mean; n = 10. *P < 0.05, **P < 0.01, and ***P < 0.001 vs vehicle group. IV intravenous administration, SC subcutaneous administration, Pred prednisolone

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles


    1. Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. Are biologics efficacious in atopic dermatitis? A systemic review and meta-analysis. Am J Clin Dermatol. 2017;19:145–165. doi: 10.1007/s40257-017-0324-7. - DOI - PubMed
    1. Brown SJ. What progress have we made in the treatment of atopic eczema? Putting the new biological therapies into a wider context. Br J Dermatol. 2017;177:4–6. doi: 10.1111/bjd.15646. - DOI - PubMed
    1. Shin TH, Kim HS, Cho SW, Kang KS. Mesenchymal stem cell therapy for inflmmatory skin diseases: clinical potential and mode of action. Int J Mol Sci. 2017;18:244. doi: 10.3390/ijms18020244. - DOI - PMC - PubMed
    1. Lou G, Chen Z, Zheng M, Liu Y. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med. 2017;49:e346. doi: 10.1038/emm.2017.63. - DOI - PMC - PubMed
    1. Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI insight. 2018;3:e99263. doi: 10.1172/jci.insight.99263. - DOI - PMC - PubMed

Publication types

MeSH terms